---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-22-000470"
form_type: "8-K"
ticker: "KAVL"
cik: "0001762239"
company_name: "Kaival Brands Innovations Group, Inc."
filed_at: "2022-03-17T23:59:59+00:00"
generated_at: "2026-06-26T22:04:04.781351+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kaival Brands Q1 revenue plunges 93% to $2.8M; net loss $2.8M; FDA stay granted

## Summary
- Revenue $2.8M vs $37.4M YoY, down 93% due to FDA MDO and competition.
- Net loss $2.8M ($0.09 loss per share) vs net income $0.3M ($0.01 EPS) YoY.
- Gross loss $700K (negative 24.3% margin) vs $4.8M gross profit (11.2% margin) YoY.
- Judicial stay of FDA Marketing Denial Order granted Feb 1, 2022; expects to resume flavored BIDI Stick sales.
- Regained Nasdaq minimum bid price compliance on Feb 18, 2022.

## SEC filing metadata
- accession: 0001731122-22-000470
- form_type: 8-K
- ticker: KAVL
- cik: 0001762239
- company_name: Kaival Brands Innovations Group, Inc.
- filed_at: 2022-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762239/000173112222000470/0001731122-22-000470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762239/000173112222000470/e3621_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-22-000470
- JSON: https://secwatch.observer/filing/0001731122-22-000470.json
- Plain text: https://secwatch.observer/filing/0001731122-22-000470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.